All In Biotech

Drug Trial Radar · NCT07947173

Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Immorna Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.

Conditions

  • Herpes Zoster (HZ)

Interventions

  • JCXH-105Biological

    Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

  • PlaceboDrug

    Placebo (sodium chloride injection) as control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serious adverse events (SAEs)Time frame: From Day 1 post- administration through 360 days after the full-course vaccination
  2. Solicited local injection site adverse eventsTime frame: Within 14 days after each dose of investigational vaccine/placebo
  3. Solicited systemic adverse eventsTime frame: Within 14 days after each dose of the investigational vaccine/placebo
  4. Unsolicited AEsTime frame: Within 30 days after each dose of the investigational vaccine/placebo
  5. Laboratory parametersTime frame: On the third day after each dose of the investigational vaccine/placebo
  6. Adverse events of special interest (AESIs)Time frame: From Day 1 post administration through 360 days after the full-course vaccination

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.